SG11201510157YA - T cell receptors - Google Patents

T cell receptors

Info

Publication number
SG11201510157YA
SG11201510157YA SG11201510157YA SG11201510157YA SG11201510157YA SG 11201510157Y A SG11201510157Y A SG 11201510157YA SG 11201510157Y A SG11201510157Y A SG 11201510157YA SG 11201510157Y A SG11201510157Y A SG 11201510157YA SG 11201510157Y A SG11201510157Y A SG 11201510157YA
Authority
SG
Singapore
Prior art keywords
cell receptors
receptors
cell
Prior art date
Application number
SG11201510157YA
Other languages
English (en)
Inventor
Peter Molloy
Original Assignee
Adaptimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Ltd filed Critical Adaptimmune Ltd
Publication of SG11201510157YA publication Critical patent/SG11201510157YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • A61K39/001181Alpha-feto protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632T-cell receptors [TCR]; antibody T-cell receptor constructs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/46448Cancer antigens from embryonic or fetal origin
    • A61K39/464481Alpha-feto protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0637Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
SG11201510157YA 2013-07-26 2014-07-18 T cell receptors SG11201510157YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1313377.2A GB201313377D0 (en) 2013-07-26 2013-07-26 T cell receptors
PCT/GB2014/052199 WO2015011450A1 (en) 2013-07-26 2014-07-18 T cell receptors

Publications (1)

Publication Number Publication Date
SG11201510157YA true SG11201510157YA (en) 2016-02-26

Family

ID=49166992

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201510157YA SG11201510157YA (en) 2013-07-26 2014-07-18 T cell receptors

Country Status (22)

Country Link
US (3) US10344074B2 (zh)
EP (2) EP3578188B1 (zh)
JP (3) JP6635311B2 (zh)
KR (2) KR102267345B1 (zh)
CN (2) CN111153984A (zh)
AU (2) AU2014294830B2 (zh)
CA (1) CA2916027C (zh)
CY (1) CY1121962T1 (zh)
DK (2) DK3024468T3 (zh)
ES (2) ES2912743T3 (zh)
GB (1) GB201313377D0 (zh)
HK (1) HK1222338A1 (zh)
HR (1) HRP20191371T1 (zh)
HU (1) HUE045399T2 (zh)
LT (1) LT3024468T (zh)
NZ (1) NZ715038A (zh)
PL (1) PL3024468T3 (zh)
PT (1) PT3024468T (zh)
RS (1) RS59177B1 (zh)
SG (1) SG11201510157YA (zh)
SI (1) SI3024468T1 (zh)
WO (1) WO2015011450A1 (zh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
CN114478791A (zh) 2015-04-03 2022-05-13 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
CN106279404A (zh) * 2015-05-20 2017-01-04 广州市香雪制药股份有限公司 一种可溶且稳定的异质二聚tcr
GB201516277D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
WO2017059557A1 (en) * 2015-10-09 2017-04-13 Peking University Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use
JP6970417B2 (ja) * 2015-10-23 2021-11-24 国立大学法人金沢大学 細胞傷害性t細胞の作製方法
EP3842450A1 (en) 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
JP6777841B2 (ja) * 2015-10-23 2020-10-28 国立大学法人金沢大学 細胞傷害性t細胞の作製方法
DK3494133T3 (da) * 2016-08-02 2022-09-19 Us Health Anti-kras-g12d-t-cellereceptorer
CA3059755A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
CN110662760A (zh) * 2017-05-12 2020-01-07 奥古斯塔大学研究所公司 人甲胎蛋白特异性t细胞受体及其用途
JP2021514188A (ja) 2018-02-15 2021-06-10 メモリアル スローン ケタリング キャンサー センター Foxp3標的因子組成物と養子細胞療法のための使用方法
CN110407927B (zh) * 2018-04-26 2022-09-09 香雪生命科学技术(广东)有限公司 一种识别afp抗原的tcr
CN110776562B (zh) * 2018-07-30 2022-06-17 香雪生命科学技术(广东)有限公司 一种识别afp抗原的t细胞受体
EP3854802A4 (en) * 2018-09-21 2022-10-12 XLifeSc, Ltd. HIGH AFFINITY T-LYMPHOCYTE RECEPTOR RECOGNIZING AFP ANTIGEN
CN110950949B (zh) * 2018-09-26 2022-04-05 香雪生命科学技术(广东)有限公司 一种识别ssx2抗原的t细胞受体
CA3119911A1 (en) * 2018-11-14 2020-05-22 Xlifesc, Ltd. High affinity tcr for afp recognition
CN111662374B (zh) * 2019-03-08 2023-01-24 香雪生命科学技术(广东)有限公司 一种识别afp抗原的高亲和力tcr
CN111748027A (zh) * 2019-03-29 2020-10-09 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
AU2019459479A1 (en) * 2019-07-30 2022-03-24 Xlifesc, Ltd. T cell receptor for recognizing SSX2 antigen short peptide
WO2021022447A1 (zh) * 2019-08-05 2021-02-11 广东香雪精准医疗技术有限公司 识别afp抗原短肽的t细胞受体
EP4013857A1 (en) 2019-08-13 2022-06-22 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily
CN112390875B (zh) * 2019-08-16 2023-01-24 香雪生命科学技术(广东)有限公司 一种识别afp的高亲和力t细胞受体
CN113072636B (zh) * 2020-01-06 2024-05-28 香雪生命科学技术(广东)有限公司 一种识别afp的t细胞受体及其编码序列
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
CN115087489A (zh) * 2020-02-14 2022-09-20 艾达普特免疫有限公司 癌症或肿瘤的治疗方法
CN113321727B (zh) * 2020-02-28 2024-04-09 香雪生命科学技术(广东)有限公司 一种识别afp抗原短肽的t细胞受体及其编码序列
CN113321725A (zh) * 2020-02-28 2021-08-31 香雪生命科学技术(广东)有限公司 一种识别afp的t细胞受体
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN115160432A (zh) * 2021-04-02 2022-10-11 香雪生命科学技术(广东)有限公司 识别afp的t细胞受体
CN115181177A (zh) * 2021-04-02 2022-10-14 香雪生命科学技术(广东)有限公司 针对afp的t细胞受体
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023137472A2 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Kras g12d調節化合物
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL208712B1 (pl) * 2001-08-31 2011-05-31 Avidex Ltd Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
GB0223399D0 (en) * 2002-10-09 2002-11-13 Avidex Ltd Receptors
JP5563194B2 (ja) 2004-06-29 2014-07-30 イムノコア リミテッド 改変t細胞レセプターを発現する細胞
US20090304657A1 (en) * 2006-05-03 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 T細胞レセプターβ鎖遺伝子及びα鎖遺伝子
DK2288700T3 (en) * 2008-05-09 2017-05-22 Agency Science Tech & Res HBV EPITOP-REACTIVE EXOGEN T-CELL RECEPTOR (TCR) AND APPLICATIONS THEREOF
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
CN105524176B (zh) * 2010-05-21 2021-03-19 银溪制药股份有限公司 双特异性融合蛋白
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors

Also Published As

Publication number Publication date
HRP20191371T1 (hr) 2019-11-01
ES2734190T3 (es) 2019-12-04
CN111153984A (zh) 2020-05-15
CA2916027A1 (en) 2015-01-29
US20160137715A1 (en) 2016-05-19
CN105408353B (zh) 2020-05-19
KR102267345B1 (ko) 2021-06-22
AU2020202538A1 (en) 2020-05-07
DK3024468T3 (da) 2019-07-22
AU2014294830A1 (en) 2016-01-21
PT3024468T (pt) 2019-08-01
JP6635311B2 (ja) 2020-01-22
DK3578188T3 (da) 2022-05-02
GB201313377D0 (en) 2013-09-11
EP3578188B1 (en) 2022-02-23
WO2015011450A1 (en) 2015-01-29
PL3024468T3 (pl) 2019-12-31
JP6956164B2 (ja) 2021-10-27
NZ715038A (en) 2021-12-24
EP3578188A1 (en) 2019-12-11
CN105408353A (zh) 2016-03-16
LT3024468T (lt) 2019-09-25
CY1121962T1 (el) 2020-10-14
RS59177B1 (sr) 2019-10-31
AU2014294830B2 (en) 2020-01-16
JP2021151248A (ja) 2021-09-30
US10344074B2 (en) 2019-07-09
JP2020054364A (ja) 2020-04-09
US20190330301A1 (en) 2019-10-31
HK1222338A1 (zh) 2017-06-30
CA2916027C (en) 2022-11-29
KR20210073612A (ko) 2021-06-18
US20210324036A1 (en) 2021-10-21
HUE045399T2 (hu) 2019-12-30
ES2912743T3 (es) 2022-05-27
SI3024468T1 (sl) 2019-10-30
KR20160034329A (ko) 2016-03-29
US11084862B2 (en) 2021-08-10
JP2016525537A (ja) 2016-08-25
EP3024468B1 (en) 2019-05-08
EP3024468A1 (en) 2016-06-01

Similar Documents

Publication Publication Date Title
HK1222338A1 (zh) 細胞受體
HK1223554A1 (zh) 細胞
HK1221724A1 (zh) 細胞受體
AU356417S (en) Battery
EP3062378A4 (en) FUEL CELL
EP2955778A4 (en) FUEL CELL
GB201303814D0 (en) Battery structure
EP2988346A4 (en) CELL HOUSING
EP2950377A4 (en) FUEL CELL
EP3067906A4 (en) ELECTROCHEMICAL DEVICE
GB201312332D0 (en) Cell locations
GB201310031D0 (en) Cell
EP2953200A4 (en) BATTERY
GB201322430D0 (en) T cell receptors
HK1218647A1 (zh) 血管加壓素- 受體激動劑
GB201312803D0 (en) Cell component
GB201317614D0 (en) Fuel cell
GB201518180D0 (en) Fuel cell
GB201320573D0 (en) T Cell
GB201317589D0 (en) Cell
GB2511577B (en) Carrying structure
GB201303132D0 (en) Cell Line
TWM476369U (en) Battery structure improvement
GB201201418D0 (en) T Cell receptors
AP2013006754A0 (en) Pylon